AR and posterior cortical atrophy: The emergence of constitutively-active AR splice variants in CRPCa, particularly AR-V7, poses a major clinical challenge as these variants not only seem to mediate resistance to novel inhibitors of androgen biosysthesis and ligand-dependent AR activity in PCa models13, 19 but also appears to accurately predict response to treatment with these drugs in CRPCa patients6.